PI3K Inhibitor Trial Showed Survival Benefit
A new targeted therapy study suggests potential for patients with advanced malignancies like uveal melanoma.
Updated on Oct. 14, 2026 in Cancer
Live Poll
Should developers prioritize creating new cancer drugs for rare solid tumor indications?
Researchers reported phase 1 trial results for roginolisib, an oral therapy designed to treat advanced solid and hematologic cancers. The study of 44 patients showed a median overall survival of 20.8 months.
Why it matters
Currently, no PI3K delta inhibitors are approved for solid tumor indications, making this a potential new avenue for treating cancers like uveal melanoma. Researchers are investigating this approach because immunosuppression often drives the progression of these malignancies.
In a phase 1 trial of 44 patients with advanced malignancies, researchers observed a median overall survival of 20.8 months. While these preliminary results are promising, the study was designed primarily for safety and dose determination.
The players
iOnctura
A biotechnology company focused on developing small-molecule therapies that target cancer signaling pathways.
Merck KGaA
A global science and technology company with significant portfolios in oncology and biopharmaceutical research.
The details
Roginolisib works by binding into a unique site within the inactive state of the PI3K delta enzyme. This action forces a conformational shift that prevents the enzyme from binding to ATP, effectively locking it in an inactive state to block cancer signaling. By preventing the enzyme from moving to an activated state, the drug aims to disrupt the pathways that fuel tumor growth.
Timeline
2017: iOnctura spun out of a development pact with Merck KGaA.
October 14, 2026: Clinical trial results were published.
Health Landscape
The development of PI3K delta inhibitors has historically focused on hematologic cancers, but this study moves the field toward potential applications in solid tumors. This trial marks a shift by attempting to address solid tumor indications where no similar drugs are currently approved.
These findings are preliminary and represent early-stage research, meaning they do not currently change clinical standards of care. Patients with uveal melanoma or other advanced malignancies should discuss evolving trial options and targeted therapy developments with their oncologist.
The takeaway
Roginolisib shows early promise as a targeted therapy that may overcome the signaling pathways used by certain solid tumors. Patients should monitor major cancer registry sites for future phase 2 trial announcements as this treatment continues through the development pipeline.
Further reading
For more information on current treatment trends, visit the Cancer section.
Source note: This article includes information reported by FierceBiotech - free daily biotech briefing.
Live Poll
Should developers prioritize creating new cancer drugs for rare solid tumor indications?
